PSTV 8-K — Smart Summary

Plus Therapeutics, Inc. (PSTV) received a letter from Nasdaq on August 22, 2025 confirming compliance with Nasdaq Listing Rule 5550(b) under both the Market Value of Listed Securities standard and the stockholders' equity standard, and was granted an extended deadline through November 12, 2025 to regain compliance with the $1.00 bid price rule.

• Nasdaq confirmed compliance with MVLS standard under Rule 5550(b)(2), requiring market value of listed securities of at least $35 million
• Nasdaq confirmed compliance with stockholders' equity standard under Rule 5550(b)(1), requiring stockholders' equity of at least $2.5 million
• Bid price rule compliance deadline extended to November 12, 2025; prior deadline of September 8, 2025 no longer applies
• Company subject to a one-year panel monitoring period through August 22, 2026 solely with respect to the Equity Standard
• If Equity Standard compliance is lost during monitoring period and no alternative standard is met, Nasdaq will issue a delist determination letter with no additional cure period granted